SLAMF7 Signaling Reprograms T Cells Toward Exhaustion in the Tumor Microenvironment
Overview
Authors
Affiliations
T cell exhaustion represents one of the most pervasive strategies tumors employ to circumvent the immune system. Although repetitive, cognate TCR signaling is recognized as the primary driving force behind this phenomenon, and it remains unknown what other forces drive T cell exhaustion in the tumor microenvironment (TME). In this study, we show that activation of the self-ligand SLAMF7 immune receptor on T cells induced STAT1 and STAT3 phosphorylation, expression of multiple inhibitory receptors, and transcription factors associated with T cell exhaustion. Analysis of The Cancer Genome Atlas revealed that SLAMF7 transcript levels were strongly correlated with various inhibitory receptors and that high SLAMF7 expression was indicative of poor survival in clear cell renal cell carcinoma (ccRCC). Targeted reanalysis of a CyTOF dataset, which profiled the TME in 73 ccRCC patients, revealed cell-type-specific SLAMF7 expression patterns, strong correlations between exhausted T cells and SLAMF7 tumor-associated macrophages (TAMs), and a unique subset of SLAMF7CD38 TAMs. These SLAMF7CD38 TAMs showed the strongest correlations with exhausted T cells and were an independent prognostic factor in ccRCC. Confirmatory ex vivo coculture studies validated that SLAMF7-SLAMF7 interactions between murine TAMs and CD8 T cells induce expression of multiple inhibitory receptors. Finally, mice lacking SLAMF7 show restricted growth of B16-F10 tumors, and CD8 T cells from these mice express less PD-1 and TOX and exhibited an impaired ability to progress through the exhaustion developmental trajectory to terminal exhaustion. These findings suggest that SLAMF7 might play an important role in modulating T cell function in the TME.
Myeloid cells meet CD8 T cell exhaustion in cancer: What, why and how.
Zhai Y, Liang X, Deng M Chin J Cancer Res. 2025; 36(6):616-651.
PMID: 39802897 PMC: 11724180. DOI: 10.21147/j.issn.1000-9604.2024.06.04.
Shi Z, Qin H, Wu H J Inflamm Res. 2024; 17:11375-11402.
PMID: 39735894 PMC: 11675326. DOI: 10.2147/JIR.S474211.
SLAMF7 defines subsets of human effector CD8 T cells.
Kared H, Tan C, Narang V, Tan S, Xian C, Wei A Sci Rep. 2024; 14(1):30779.
PMID: 39730488 PMC: 11680708. DOI: 10.1038/s41598-024-80971-5.
Lawton M, Inge M, Blum B, Smith-Mahoney E, Bolzan D, Lin W PLoS Biol. 2024; 22(12):e3002943.
PMID: 39689157 PMC: 11703073. DOI: 10.1371/journal.pbio.3002943.
Shi Y, Zhao W, Ding Y, Ge X, Ju M Front Immunol. 2024; 15:1467098.
PMID: 39687627 PMC: 11647020. DOI: 10.3389/fimmu.2024.1467098.